In 2003, Dr. O’Neill joined Biogen as an associate director of clinical development, making the transition from practicing neurology full-time at Massachusetts General Hospital (MGH) to industry. During his 15-year career with Biogen, Dr. O’Neill held leadership roles of increasing responsibility in clinical research and development. From November 2016 to June 2018, Dr. O’Neill served as Biogen’s senior vice president, late-stage clinical development and oversaw development programs for Alzheimer’s disease, movement disorders, acute neurology, multiple sclerosis, pain, neuromuscular disease, gene and cell therapy, and rare diseases. He played a leadership role in seeking, receiving and maintaining global marketing approvals for Tecfidera®, Zinbryta®, Plegridy® and Spinraza®. Dr. O’Neill is a member of the American Academy of Neurology and a board-certified neurologist (ABPN), licensed to practice medicine in the state of Massachusetts. He served as director of the leukodystrophy service and chief resident in neurology during his time at MGH as full-time physician, and has maintained his clinical appointment at MGH with a sub-specialty interest in neuromuscular diseases and inherited leukodystrophies. From 1997 to 2015, he served as a clinical instructor in neurology at Harvard Medical School. Dr. O’Neill also serves on the board of directors of the Massachusetts Biotechnology Council (MassBio). Dr. O’Neill received a Bachelor of Medicine degree at University College Dublin and a Master of Medical Sciences degree from Harvard University. He is the recipient of numerous awards in science and medicine, including the Lefler Fellowship in the Department of Neurobiology at Harvard Medical School. Dr. O’Neill is the author of numerous publications on multiple sclerosis, has served as a neurology peer reviewer for medical literature, and lectures in the United States and globally on advances in neurology and neurological research.